| Target Price | ₩346,800.00 |
| Price | ₩155,300.00 |
| Potential |
123.31%
register free of charge
|
| Number of Estimates | 29 |
|
29 Analysts have issued a price target Hybe 2027 .
The average Hybe target price is ₩346,800.00.
This is
123.31%
register free of charge
₩472,500.00
204.25%
register free of charge
₩212,100.00
36.57%
register free of charge
|
|
| A rating was issued by 33 analysts: 32 Analysts recommend Hybe to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hybe stock has an average upside potential 2027 of
123.31%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ₩ | 2,649.87 | 4,807.53 |
| 17.48% | 81.42% | |
| EBITDA Margin | 6.02% | 9.63% |
| 54.77% | 59.99% | |
| Net Margin | -8.95% | 4.58% |
| 2,253.35% | 151.15% |
29 Analysts have issued a sales forecast Hybe 2026 . The average Hybe sales estimate is
This results in the following potential growth metrics:
28 Analysts have issued an Hybe EBITDA forecast 2026. The average Hybe EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Hybe Analysts have issued a net profit forecast 2026. The average Hybe net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ₩ | -5,690.43 | 5,195.78 |
| 2,624.26% | 191.31% | |
| P/E | 29.89 | |
| EV/Sales | 1.24 |
29 Analysts have issued a Hybe forecast for earnings per share. The average Hybe EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


